NCT00002266View on ClinicalTrials.gov

An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients

NACompletedINTERVENTIONAL

Timeline

Start Date

Not specified

Conditions

HIV Infections

Interventions

DRUG

AS-101

Trial Locations (1)

85724

Univ of Arizona / Health Science Ctr, Tucson

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00002266 - An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients | Biotech Hunter | Biotech Hunter